NO20076053L - Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom - Google Patents

Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom

Info

Publication number
NO20076053L
NO20076053L NO20076053A NO20076053A NO20076053L NO 20076053 L NO20076053 L NO 20076053L NO 20076053 A NO20076053 A NO 20076053A NO 20076053 A NO20076053 A NO 20076053A NO 20076053 L NO20076053 L NO 20076053L
Authority
NO
Norway
Prior art keywords
prevention
treatment
pyrazolopyrimidine derivative
present
portal
Prior art date
Application number
NO20076053A
Other languages
English (en)
Inventor
Seul Min Choi
Byoung Ok Ahn
Moohi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of NO20076053L publication Critical patent/NO20076053L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Farmasøytisk blanding for behandling og forebygging av leversykdommer inneholder pyrazolpyrimidinonderivat som aktiv bestanddel. Pyrazolpyrimidinonderivatet inhiberer kollagensyntese i hepatiske stellatceller og virker direkte på den portale venen. Det kan øke diameteren og mengden av blodstrøm gjennom den portale venen, og til slutt redusere trykket i samme. Pyrazolpyrimidinonderivat kan med fordel brukes til å behandle og forebygge hepatisk fibrose, levercirrhose forårsaket av hepatisk fibrose, portal hypertensjon og ulike komplikasjoner forårsaket av portal hypertensjon. I tillegg kan pyrazolpyrimidinonderivat redusere doseringshyppighet på grunn av dets lange halveringstid, og har derfor en fordel at det forbedrer medgjørlighet hos pasienter som lider av kroniske leversykdommer.
NO20076053A 2005-06-10 2007-11-26 Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom NO20076053L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050050033 2005-06-10
PCT/KR2005/003526 WO2006132460A1 (en) 2005-06-10 2005-10-21 Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Publications (1)

Publication Number Publication Date
NO20076053L true NO20076053L (no) 2008-02-27

Family

ID=37498629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076053A NO20076053L (no) 2005-06-10 2007-11-26 Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom

Country Status (21)

Country Link
US (1) US8796286B2 (no)
EP (1) EP1888074B1 (no)
JP (1) JP4879977B2 (no)
KR (1) KR100914445B1 (no)
CN (1) CN101193636B (no)
AT (1) ATE537832T1 (no)
AU (1) AU2005332719B2 (no)
BR (1) BRPI0520209A2 (no)
CA (1) CA2611638C (no)
CY (1) CY1112637T1 (no)
DK (1) DK1888074T3 (no)
ES (1) ES2376628T3 (no)
IL (1) IL187678A (no)
MX (1) MX2007015365A (no)
NO (1) NO20076053L (no)
NZ (1) NZ564369A (no)
PT (1) PT1888074E (no)
RU (1) RU2369392C2 (no)
UA (1) UA86528C2 (no)
WO (1) WO2006132460A1 (no)
ZA (1) ZA200800180B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954295B2 (ja) * 2006-12-28 2012-06-13 インセクト バイオテック カンパニー， リミティッド アラザイムを有効成分とする肝機能保護用薬学的組成物
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
EP2873017B1 (en) * 2012-07-11 2021-09-01 University of Mississippi Medical Center Method for the detection and staging of liver fibrosis from image acquired data
US9693998B2 (en) 2014-05-16 2017-07-04 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
US12161632B2 (en) 2014-05-16 2024-12-10 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
AU2016285566A1 (en) 2015-06-30 2017-12-14 Cumberland Pharmaceuticals, Inc. Thromboxane receptor antagonists in AERD/asthma
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
AU2020356193A1 (en) 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
JP2024532957A (ja) * 2021-08-13 2024-09-10 メジオン ファーマ カンパニー リミテッド ウデナフィル組成物を用いた線維肝状態を処置する方法および組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
KR100377782B1 (ko) 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
AU2003286555A1 (en) * 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004108662A1 (ja) 2003-05-15 2004-12-16 Kumiai Chemical Industry Co., Ltd. フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2528975A1 (en) * 2003-06-10 2004-12-16 Pfizer Inc. Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
DE102005001989A1 (de) 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren

Also Published As

Publication number Publication date
WO2006132460A1 (en) 2006-12-14
EP1888074A1 (en) 2008-02-20
ATE537832T1 (de) 2012-01-15
CN101193636A (zh) 2008-06-04
NZ564369A (en) 2010-03-26
EP1888074A4 (en) 2010-06-23
BRPI0520209A2 (pt) 2009-04-22
US8796286B2 (en) 2014-08-05
ES2376628T3 (es) 2012-03-15
AU2005332719B2 (en) 2010-05-13
CA2611638C (en) 2010-08-24
JP4879977B2 (ja) 2012-02-22
EP1888074B1 (en) 2011-12-21
US20080207646A1 (en) 2008-08-28
IL187678A (en) 2013-04-30
CN101193636B (zh) 2011-12-28
IL187678A0 (en) 2008-11-03
ZA200800180B (en) 2009-01-28
KR100914445B1 (ko) 2009-08-28
CY1112637T1 (el) 2016-02-10
RU2007149474A (ru) 2009-07-20
KR20060128605A (ko) 2006-12-14
MX2007015365A (es) 2008-02-12
JP2008543748A (ja) 2008-12-04
UA86528C2 (uk) 2009-04-27
AU2005332719A1 (en) 2006-12-14
DK1888074T3 (da) 2012-01-23
HK1119596A1 (en) 2009-03-13
RU2369392C2 (ru) 2009-10-10
CA2611638A1 (en) 2006-12-14
PT1888074E (pt) 2012-03-01

Similar Documents

Publication Publication Date Title
ZA200800180B (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20075136L (no) Nye liposompreparater
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
CY1118179T1 (el) Φαρμακευτικη συνθεση
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
CO5590918A2 (es) Formulaciones
EA200501203A1 (ru) Жидкие фармацевтические композиции палоносетрона
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
NO20070832L (no) Farmasoytiske preparat av piperazinderivater.
IL191670A0 (en) Compounds for the inhibition of apoptosis
SE0303135D0 (sv) Controlled food effect composition
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
MY148300A (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application